



Check for updates

Cite this: DOI: 10.1039/d5ob00406c

## A self-assembled fluorescent probe for H<sub>2</sub>O<sub>2</sub> detection in NAFLD diagnosis

 Mengzhao Zhang,<sup>a</sup> Junlei Hao,<sup>b</sup> Chengcheng Wu,<sup>a</sup> Suntao Shi,<sup>a</sup> Zhengyu Ma,<sup>a</sup> Xiaowen Ren,<sup>a</sup> Fei Han,<sup>a</sup> Jiang Wu,<sup>b</sup> Haijuan Zhang<sup>\*a</sup> and Baoxin Zhang<sup>ID</sup> <sup>\*a</sup>

Nonalcoholic fatty liver disease (NAFLD) is an epidemic metabolic disorder of the liver involving a constellation of pathological processes. There is accumulating evidence that oxidative stress is an influential mechanism leading to NAFLD. Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) is a major ROS molecule involved in many biological processes in the human body and one of the primary triggers of oxidative stress. Consequently, the monitoring of alterations in H<sub>2</sub>O<sub>2</sub> levels within organisms is imperative for research pertaining to NAFLD. Herein, we have tailored and synthesized **CM-CN**, a novel fluorescent probe for the detection of H<sub>2</sub>O<sub>2</sub> without autofluorescence, which is capable of interacting with H<sub>2</sub>O<sub>2</sub> and then spontaneously generating iminocoumarins with high red emissive fluorescence based on a cascade reaction. Furthermore, the probe demonstrated excellent performance, including a low detection limit (LOD = 44.362 nM) and a large Stokes shift ( $\Delta\lambda > 100$  nm). In addition, it exhibited the capacity to monitor alterations in H<sub>2</sub>O<sub>2</sub> levels in zebrafish and mouse models of NAFLD. These results illustrate the great potential of this probe as a transformative tool that could advance fundamental research in reactive oxygen species biology, especially in hepatic steatosis and oxidative stress-related diseases.

Received 6th March 2025,  
Accepted 12th August 2025

DOI: 10.1039/d5ob00406c

rsc.li/obc

### 1. Introduction

Non-alcoholic fatty liver disease (NAFLD) is a common liver metabolic disorder characterized by the accumulation of fat in the liver. If left untreated, it may progress to steatohepatitis, cirrhosis, and even hepatocellular carcinoma.<sup>1–4</sup> The pathological processes of this disease are complex, with oxidative stress playing a crucial role in the onset and progression of NAFLD.<sup>5–8</sup> Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), one of the ROS molecules, plays a pivotal role in numerous biological processes within the body and is recognised as a significant contributor for the onset of oxidative stress.<sup>9–12</sup> Accumulating proofs reveal that one of the most important mechanisms contributing to NAFLD is oxidative stress.<sup>13–17</sup> Hence, there is a pressing necessity for a methodology capable of precise detection of hydrogen peroxide in the liver, thereby facilitating the comprehension of liver-related pathologies and the development of therapeutic interventions.

Fluorescent probes have proven to be exceptionally advantageous in the identification of biological small molecules, protein labeling and disease diagnostics, establishing themselves as some of the most convenient and sought-after tools


for exploring complex biological processes.<sup>18–22</sup> At present, many fluorescent probes have been widely used for detecting H<sub>2</sub>O<sub>2</sub> in living cells. It is evident that these probes have demonstrated remarkable advancements in multiple fronts. Examples of such properties include extremely rapid response times and superior biomonitoring capabilities resulting from NIR emission, *etc.*<sup>23–26</sup> However, there are certain challenges persisting for these probes, particularly the interference from the background fluorescence of the probe, which has the potential to affect the accuracy of bioimaging studies. Consequently, there is an urgent requirement for a novel probe capable of effectively eliminating background fluorescence interference and enhancing detection accuracy.<sup>27–30</sup>

With the above considerations, we have conceived and synthesized a probe **CM-CN** that can be activated by H<sub>2</sub>O<sub>2</sub> based on a cascade intramolecular cyclization reaction, which is different from the common fluorescent probes that use various groups to quench the luminescence effect of the fluorophore (Table S1), instead of constructing a series of specific structures to enable the probe, which is devoid of fluorophores, to generate fluorophores to produce fluorescence by a self-assembled tandem cyclisation reaction after reacting with the detector<sup>31–35</sup> (Fig. 1). Therefore, in comparison with alternative probes, **CM-CN** is not subject to interference from probe autofluorescence and exhibits reduced interference in bioimaging, rendering it more suitable for bioimaging applications. The probe interacts with H<sub>2</sub>O<sub>2</sub> and generates a cou-


<sup>a</sup>State Key Laboratory of Applied Organic Chemistry and College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China

<sup>b</sup>Key Laboratory for Tibet Plateau Phytochemistry of Qinghai Province, College of Pharmacy, Qinghai Minzu University, Xining 810007, Qinghai, P. R. China

## A Previous work



## B This work



**Fig. 1** (A) Traditional strategy of probe design. (B) Our novel strategy of probe design by cascade self-assembly.

marin derivative by intramolecular cyclization. The conjugation between the electron-donating amino group and the electron-withdrawing cyano group in this coumarin derivative endows it with an intramolecular charge transfer (ICT) effect, which results in a large Stokes shift for this fluorophore. A sequence of tests was performed to validate the performance of the probe. The results showed that **CM-CN** exhibits excellent detection and selectivity for  $\text{H}_2\text{O}_2$ , with no background fluorescence and low probe toxicity, which indicates that it is suitable for bioimaging. It is worth noting that the probe could be used to monitor changes in  $\text{H}_2\text{O}_2$  concentration *in vivo* through fluorescence imaging and noninvasively characterize fatty liver in mice, thereby differentiating between healthy and fatty liver states. Hence, the probe enhances early detection and monitoring of  $\text{H}_2\text{O}_2$ -related diseases such as fatty liver by being responsive to changes in  $\text{H}_2\text{O}_2$ .

## 2. Experimental section

### 2.1. Materials and instruments

All chemical precursors employed in organic synthesis met analytical grade specifications, procured through the Titan Discovery platform without requiring additional purification. Reagents were commercially sourced unless otherwise specified, with all solvents subjected to standard purification protocols prior to experimental use. Cell culture components, including Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum were sourced from Wuhan Pricella Biotechnology Ltd., while chromatographic-grade silica gel was supplied by Yantai Xinnuo New Material Technology Ltd. Biological materials comprised HepG2 hepatocytes (acquired from Lanzhou University School of Medicine), zebrafish strains (Experimental Zebrafish Germplasm Resource Centre), and specific pathogen-free (SPF) male Kunming mice (Laboratory Animal Centre of Lanzhou University). Structural characterization was performed using Bruker nuclear magnetic resonance spectrometers ( $^1\text{H}/^{13}\text{C}$  NMR) complemented by Thermo Scientific high-resolution mass spectrometry. Optical properties were analyzed *via* Thermo Scientific 220 UV-Vis spectrophotometry and Agilent fluorescence spectrophotometry. Subcellular fluorescence imaging utilized a Zeiss LSM

880 NLO confocal microscope, while *in vivo* biodistribution studies employed a Bruker Xtreme II imaging system with multispectral capabilities. The experimental protocols that involved the use of animals were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals established by the National Institutes of Health and were approved by the Ethics Committee of Lanzhou University.

### 2.2. Synthesis of CM-CN

The synthetic routes of **CM-CN** are illustrated in Scheme 1. The specific synthetic steps, as well as their compound characterisation, are elucidated in the SI.


### 2.3. Spectrometric analysis

Stock solutions of **CM-CN** were prepared at 1 mM concentration through dissolution in dimethyl sulfoxide (DMSO), followed by storage under dark conditions at  $-20\text{ }^\circ\text{C}$ . Working solutions were prepared by diluting the stock solution with phosphate-buffered saline (PBS, pH 7.4) to achieve a final concentration of 100  $\mu\text{M}$ , which were subsequently subjected to spectroscopic characterization, including fluorescence emission and UV-visible absorption measurements. To assess the probe's selectivity profile, potential interferents ( $\text{CuNO}_3$ ;  $\text{CuSO}_4$ ;  $\text{FeCl}_2$ ;  $\text{FeCl}_3$ ;  $\text{KNO}_3$ ;  $\text{Na}_2\text{CO}_3$ ;  $\text{NaCl}$ ;  $\text{NaHS}$ ;  $\text{NaHSO}_3$ ;  $\text{Glu}$ ;  $\text{Thr}$ ;  $\text{Ala}$ ;  $\text{Lys}$ ;  $\text{Leu}$ ;  $\text{Pro}$ ;  $\text{Arg}$ ;  $\text{Ser}$ ;  $\text{Gln}$ ;  $\text{His}$ ;  $\text{Met}$ ;  $\text{Asn}$ ;  $\text{Cys}$ ;  $\text{Tyr}$ ;  $\text{O}^{2-}$ ;  $\text{Val}$ ;  $\text{Asp}$ ;  $\text{Hcy}$ ;  $\text{GSH}$ ;  $\text{Ile}$ ;  $\text{Gly}$ ;  $\text{Phe}$ ;  $\text{Trp}$ ;  $\text{OCl}^-$ ;  $\text{TBHP}$ ;  $\text{AAPH}$ ;  $^t\text{OtBu}$ ;  $^t\text{OH}$ ;  $\text{NO}$ ;  $^1\text{O}_2$ ;  $\text{ONOO}^-$ ) were individually prepared at 1 mM concentration in ultrapure water and introduced into the probe solution for interference testing.

### 2.4. Cytotoxicity assay and cell imaging

The experimental procedures utilized HepG2 cell models maintained in DMEM-based culture medium (enriched with 10% thermally inactivated fetal bovine serum from Pricella) containing 1% antibiotics (Sangon; 100  $\text{U mL}^{-1}$  penicillin and 100  $\mu\text{g mL}^{-1}$  streptomycin). All cell cultures were maintained under standardized conditions: a humidified atmosphere containing 5%  $\text{CO}_2$  at 37  $^\circ\text{C}$ .

Cell viability assessment was performed through CCK-8 cytotoxicity analysis (Cell Counting Kit-8, Adamas-life) to evaluate the biological effects of **CM-CN**. Cell suspensions ( $1 \times 10^4$  cells per well) were plated in 96-well culture plates containing



**Scheme 1** The synthetic route of **CM-CN**. Reagents and conditions: (a) dimethylamine,  $\text{Na}_2\text{S}_2\text{O}_5$ ,  $\text{H}_2\text{O}$ , 140  $^\circ\text{C}$ ; (b)  $\text{POCl}_3$ , DMF, 50  $^\circ\text{C}$ ; (c) 4-(bromomethyl)benzeneboronic acid pinacol ester,  $\text{K}_2\text{CO}_3$ , 85  $^\circ\text{C}$ ; (d) dimalononitrile, piperidine,  $\text{CH}_3\text{COOH}$ , EtOH, 85  $^\circ\text{C}$ .

100  $\mu\text{L}$  of complete growth medium and maintained under standard culture conditions (37  $^{\circ}\text{C}$ , 5%  $\text{CO}_2$ ). Following 12 h of incubation to ensure cell adhesion, the culture supernatant was aspirated and replaced with fresh DMEM basal medium. **CM-CN** solutions were administered at varying concentrations (12.5, 25, 50, 100, and 200  $\mu\text{M}$ ) for 12 h exposure. Post-treatment, cell metabolic activity was quantified by replacing the medium with 100  $\mu\text{L}$  of CCK-8 working solution (10% v/v) and incubating for 60 min. Optical density measurements were conducted at 460 nm wavelength using a Thermo Scientific microplate spectrophotometer.

The fluorescence-based monitoring of  $\text{H}_2\text{O}_2$  level alterations in HepG2 cells was conducted using a standardized cell treatment protocol. Cell models were subjected to pretreatment with 2 mM  $\text{H}_2\text{O}_2$  in complete growth medium for 30 min, followed by three cycles of PBS washing (10 mM, pH 7.4) prior to 60 min of incubation with 50  $\mu\text{M}$  **CM-CN**. The parallel control group was directly exposed to **CM-CN** without undergoing oxidative stimulation. Cellular imaging was performed using a laser-scanning confocal microscope, simultaneously capturing bright-field images and red fluorescence emission images for the analysis of hydrogen peroxide dynamics.

### 2.5. Zebrafish imaging experiment

For *in vivo* fluorescence analysis, larval zebrafish at 3 days post-fertilization were anesthetized and precisely positioned in specialized confocal imaging chambers. The experimental design incorporated three distinct treatment protocols: the first group received direct exposure to 50  $\mu\text{M}$  **CM-CN** for 60 min; the second group underwent sequential pretreatment with 2 mM  $\text{H}_2\text{O}_2$  for 30 min followed by 60 min of incubation with **CM-CN**; and the third group was initially treated with 20  $\mu\text{M}$  dexamethasone (DXM) for 30 min before 60 min of **CM-CN** incubation. Following probe incubation, all specimens were subjected to gentle PBS washing cycles and subsequently immobilized in imaging chambers containing minimal essential culture medium. Fluorescence acquisition was conducted using a confocal laser scanning microscope equipped with a 10 $\times$  magnification objective.

### 2.6. Living mouse imaging experiment

A murine model of NAFLD was established through combined administration of a high-fat diet (HFD) and daily intraperitoneal injections of DXM (100 mg  $\text{kg}^{-1}$ ). Control animals received equivalent volumes of saline injections and standard chow. Following the 7-day induction period, all subjects were administered **CM-CN** (100 mg  $\text{kg}^{-1}$ ) for *in vivo* hydrogen peroxide monitoring. Longitudinal fluorescence imaging was conducted using a small animal *in vivo* imaging system (IVIS) to quantify temporal changes in fluorescence intensity distribution.

## 3. Results and discussion

### 3.1 Probe design

An effective fluorescent probe must exhibit high sensitivity and stability, demonstrating significant variations in fluo-

rescence intensity across different concentrations of  $\text{H}_2\text{O}_2$ . Additionally, minimizing the intrinsic fluorescence interference from the probe itself is an essential consideration. Consequently, the selection of a molecular structure with superior fluorescence characteristics is of paramount importance. In this study, we reported the rational design and successful synthesis of a novel cascade reaction-based fluorescent probe, designated as **CM-CN**. The molecular architecture integrates  $\alpha,\beta$ -unsaturated malononitrile moieties covalently conjugated to a naphthalene core through C-C bond formation, while *p*-phenylborate groups are strategically incorporated as  $\text{H}_2\text{O}_2$ -responsive elements *via* ether linkages at the molecular periphery.


The operational mechanism of **CM-CN** involves three sequential transformations: firstly, upon  $\text{H}_2\text{O}_2$  exposure, the borate ester undergoes specific cleavage to generate a phenolic intermediate, which subsequently undergoes quinone methide elimination. This is followed by a spontaneous intramolecular cyclization process, in which the liberated phenolic group initiates a nucleophilic attack on the adjacent cyano functionality, ultimately yielding a coumarin fluorophore.

The probe's structural sophistication is further enhanced by a dimethylamino substituent positioned on the naphthalene system. This precisely engineered configuration enables effective conjugation between the electron-donating amino group and the electron-withdrawing carbonyl group in the coumarin product, establishing a robust ICT effect that manifests an exceptionally large Stokes shift ( $\Delta\lambda > 100$  nm).<sup>36,37</sup>

With the above design philosophy, the probe that we have designed not only has a significant advantage in terms of  $\text{H}_2\text{O}_2$  response but also exhibits no interference from the background fluorescence of the probe itself. These combined attributes make **CM-CN** particularly suitable for high-resolution fluorescence imaging applications. The probe's demonstrated capability for real-time  $\text{H}_2\text{O}_2$  tracking in hepatic systems shows particular promise for investigating pathological mechanisms in fatty liver disease and associated metabolic disorders, potentially enabling new approaches for early clinical intervention.

### 3.2. Spectroscopic properties of **CM-CN**

In order to validate the potential of **CM-CN** for  $\text{H}_2\text{O}_2$  fluorescence imaging, an investigation was conducted into the photophysical characteristics of the probe before and after  $\text{H}_2\text{O}_2$  exposure under various conditions. Initially, the temporal response profile of the probe to a fixed  $\text{H}_2\text{O}_2$  concentration (1 mM) was assessed, with the corresponding experimental results presented in Fig. 2A and B. Upon  $\text{H}_2\text{O}_2$  treatment, the probe exhibited a significant fluorescence enhancement, demonstrating a time-dependent increase that reached maximum intensity after 60 min of incubation, followed by signal stabilization. The fluorescence amplification factor was found to be approximately 24-fold, indicating both excellent  $\text{H}_2\text{O}_2$  responsiveness and time dependence of the probe. For evaluating the temporal stability of **CM-CN**, an *in vitro* stability experiment was performed (Fig. S1), in which **CM-CN** (100  $\mu\text{M}$ ) was incubated with  $\text{H}_2\text{O}_2$  (1 mM) for 3 h, 6 h, and 9 h, and the



**Fig. 2** (A) Fluorescence spectra of **CM-CN** (100  $\mu\text{M}$ ) incubated for different times (0–80 min) with  $\text{H}_2\text{O}_2$  (1 mM). (B) Linear correlation of **CM-CN** (100  $\mu\text{M}$ ) incubated for different times (0–80 min) with  $\text{H}_2\text{O}_2$  (1 mM). (C) Fluorescence spectra of **CM-CN** (100  $\mu\text{M}$ ) incubated with different concentrations of  $\text{H}_2\text{O}_2$ . (D) Linear correlation of **CM-CN** (100  $\mu\text{M}$ ) in response to  $\text{H}_2\text{O}_2$  (0–1 mM).

fluorescent signal was monitored for 9 h without any attenuation, confirming that **CM-CN** has significant temporal stability.

In an effort to ascertain the concentration-dependent response of **CM-CN** to  $\text{H}_2\text{O}_2$ , a meticulous evaluation of its fluorescence behavior under varying  $\text{H}_2\text{O}_2$  concentrations was conducted under a series of standardized experimental conditions. As demonstrated in Fig. 2C and D, the fluorescence emission intensity at 565 nm exhibited a progressive enhancement that correlated with increasing  $\text{H}_2\text{O}_2$  concentrations, achieving maximal amplification approximately 22.5-fold at 1 mM  $\text{H}_2\text{O}_2$ . Furthermore, quantitative analysis revealed a strong linear correlation between fluorescence intensity and  $\text{H}_2\text{O}_2$  concentrations within the 0–1 mM range. The detection limit was calculated as 44.362 nM through standard deviation analysis (eqn (S1)). These findings collectively demonstrated that **CM-CN** possesses superior sensitivity and exhibits a pronounced concentration-dependent detection capability for  $\text{H}_2\text{O}_2$ .


Furthermore, to ascertain the validity of the mechanism proposed in Fig. 1, NMR and HRMS titration experiments were carried out for the reaction of **CM-CN** with  $\text{H}_2\text{O}_2$ . The outcomes of these experiments are encouraging, and the generation of the reaction intermediate and the end-product fluorophore, **CN-4**, was observed in the reaction solution of **CM-CN** with  $\text{H}_2\text{O}_2$  in both experiments (Fig. S2 and S3). This finding validates the proposed mechanism for the response of **CM-CN** to  $\text{H}_2\text{O}_2$  and further substantiates the viability and feasibility of the novel strategy that was devised.

### 3.3. pH stability and interference resistance of **CM-CN**

Following the attainment of compelling fluorescence outcomes for **CM-CN**, a subsequent evaluation of its performance was conducted. For the assessment of the pH-dependent stability

of **CM-CN**, we performed a comprehensive validation of its fluorescence response characteristics in different pH environments. As depicted in Fig. 3A, the probe demonstrated optimal performance within the physiological pH range (6.5–8.5), with peak fluorescence intensity observed at pH 7.4. Acidic conditions were found to significantly compromise the sensing capability, a phenomenon potentially attributable to the deprotonated state of the activated fluorophore under physiological conditions that facilitated favorable cyclization kinetics.<sup>38,39</sup> These findings strongly supported the exceptional suitability of **CM-CN** for physiological  $\text{H}_2\text{O}_2$  detection and its promising application potential in *in vivo* imaging systems.

The experimental findings collectively demonstrated that **CM-CN** exhibited exceptional sensitivity for  $\text{H}_2\text{O}_2$  detection while maintaining robust fluorescence responsiveness under physiological pH conditions. Nevertheless, the intricate interplay of biological components *in vivo* necessitated rigorous evaluation of molecular selectivity.<sup>40–42</sup> Systematic interference measurements were performed by co-incubation with various amino acids and ROS derivatives, verifying the immunity of **CM-CN** toward  $\text{H}_2\text{O}_2$ . As evidenced in Fig. 3B, **CM-CN** displayed selective activation specifically toward  $\text{H}_2\text{O}_2$  among the analytes tested, with minimal cross-reactivity observed toward other bioactive molecules. Notably, the response magnitude of the probe to  $\text{H}_2\text{O}_2$  significantly exceeded that of other ROS derivatives, exhibiting >2-fold signal superiority. This distinct response profile confirmed the remarkable molecular specificity of the probe, as its ability to detect  $\text{H}_2\text{O}_2$  remained unaffected by potential biological interferents. Such operational stability and target specificity constituted critical prerequisites for accurate quantification of  $\text{H}_2\text{O}_2$  in complex biological matrices, ensuring that observed signal variations predominantly reflected genuine  $\text{H}_2\text{O}_2$  fluctuations rather than environmental artifacts. These combined attributes established **CM-CN** as a reliable molecular tool for investigating  $\text{H}_2\text{O}_2$ -associated pathological mechanisms.



**Fig. 3** (A) Fluorescence intensity of **CM-CN** (100  $\mu\text{M}$ ) in PBS after adding 0 mM and 1 mM  $\text{H}_2\text{O}_2$  with different pH values. (B) Fluorescence response of **CM-CN** (100  $\mu\text{M}$ ) upon mixing with different species in PBS buffer. 1,  $\text{CuNO}_3$ ; 2,  $\text{CuSO}_4$ ; 3,  $\text{FeCl}_2$ ; 4,  $\text{FeCl}_3$ ; 5,  $\text{KNO}_3$ ; 6,  $\text{Na}_2\text{CO}_3$ ; 7,  $\text{NaCl}$ ; 8,  $\text{NaHS}$ ; 9,  $\text{NaHSO}_3$ ; 10, Glu; 11, Thr; 12, Ala; 13, Lys; 14, Leu; 15, Pro; 16, Arg; 17, Ser; 18, Gln; 19, His; 20, Met; 21, Asn; 22, Cys; 23, Tyr; 24,  $\text{O}^{2-}$ ; 25, Val; 26, Asp; 27, Hcy; 28, GSH; 29, Ile; 30, Gly; 31, Phe; 32, Trp; 33, OCl $^-$ ; 34, TBHP; 35, AAPH; 36,  $\text{O}^t\text{Bu}$ ; 37,  $\text{OH}^-$ ; 38, NO; 39,  $^1\text{O}_2$ ; 40, ONOO $^-$ ; 41,  $\text{H}_2\text{O}_2$ . The concentrations of small molecules and proteins were 10 eq. and 1 mM, respectively.




### 3.4. Intracellular imaging and cytotoxicity activity testing


Prior to biological imaging applications, we conducted rigorous cytocompatibility tests of **CM-CN** using HepG2 cells. Dose-response analysis revealed sustained cell viability exceeding 80% following 12 h exposure to **CM-CN** concentrations of 12.5, 25, 50, 100, and 200  $\mu\text{M}$  (Fig. S4), indicating that **CM-CN** was biocompatible and suitable for use in bioimaging applications. With the aim of accurately assessing the ability of **CM-CN** to monitor the dynamic fluctuations of  $\text{H}_2\text{O}_2$  in living systems, HepG2 cells were subjected to a standardized treatment consisting of a 30 min pre-treatment with  $\text{H}_2\text{O}_2$  and 60 min of **CM-CN** incubation, whereas a parallel control group was subjected to **CM-CN** in the absence of oxidative stimuli. Fluorescence imaging analysis (Fig. 4) revealed strong fluorescence in the  $\text{H}_2\text{O}_2$ -treated cells, whereas the other group exhibited only weak basal fluorescence. It was noteworthy that the fluorescence of the  $\text{H}_2\text{O}_2$ -incubated cells was enhanced by a factor of 2.9 when compared to the control group, and these data were also verified by quantitative detection of fluorescence. The residual fluorescence in control specimens likely originated from constitutively expressed reactive oxygen species. This orthogonal validation confirmed the capacity of **CM-CN** for selective exogenous  $\text{H}_2\text{O}_2$  detection in living cellular environments while maintaining signal fidelity against endogenous interference. The preserved dose-response correlation between *in vitro* and cellular systems established its diagnostic potential for real-time  $\text{H}_2\text{O}_2$  monitoring, with demonstrated translatability for *in vivo* imaging applications.

### 3.5. *In vivo* fluorescence imaging in zebrafish

Following the successful demonstration of the capacity of **CM-CN** for intracellular  $\text{H}_2\text{O}_2$  detection, the investigation was expanded to evaluate its imaging performance in a zebrafish model through validation of both endogenous and exogenous  $\text{H}_2\text{O}_2$  detection. The experimental design comprised three distinct groups: the negative control group underwent 60 min of incubation with 50  $\mu\text{M}$  **CM-CN** alone; the exogenous  $\text{H}_2\text{O}_2$  experimental group underwent sequential treatment with 2 mM  $\text{H}_2\text{O}_2$  (30 min) followed by **CM-CN** incubation; and the endogenous  $\text{H}_2\text{O}_2$  group was established through DXM-induced fatty liver model development prior to **CM-CN** treatment. Fluorescence imaging analysis (Fig. 5) revealed distinct response patterns: basal fluorescence in the negative control, attributable to consti-



**Fig. 4** Fluorescence confocal imaging of HepG2 cells: (A) HepG2 cells were treated with 50  $\mu\text{M}$  **CM-CN** for 60 min; HepG2 cells were treated with 2 mM  $\text{H}_2\text{O}_2$  for 30 min, and then treated with 50  $\mu\text{M}$  **CM-CN** for another 60 min. (B) Relative fluorescence intensities of the images shown in (A). Data are expressed as mean SEM (bars) ( $n = 6$ ).




**Fig. 5** Confocal laser fluorescence imaging of zebrafish: (A) zebrafish were co-incubated with 100  $\mu\text{M}$  **CM-CN** for 60 min; zebrafish were co-incubated with 1 mM  $\text{H}_2\text{O}_2$  for 30 min followed by co-incubation with 100  $\mu\text{M}$  **CM-CN** for 30 min; zebrafish were pre-treated with 20  $\mu\text{M}$  DXM for 30 min followed by 100  $\mu\text{M}$  **CM-CN** for another 30 min. (B) The relative fluorescence intensity of the picture from (A). Data are presented as mean SEM (bars) ( $n = 6$ ).

tutive ROS production, and significantly enhanced signals in both experimental groups, with 5.8-fold and 4.8-fold increases for exogenous and endogenous  $\text{H}_2\text{O}_2$  detection, respectively. The observed 17.2% signal reduction in endogenous *versus* exogenous detection reflected differential  $\text{H}_2\text{O}_2$  generation mechanisms between pharmacological induction and direct supplementation. These findings collectively demonstrated the capacity of **CM-CN** for precise quantification of both pathologically generated and externally introduced  $\text{H}_2\text{O}_2$  pools in complex organisms, establishing its diagnostic reliability as a highly sensitive and selective fluorescent probe for *in vivo* applications.

### 3.6. *In vivo* fluorescence imaging in mice with fatty liver

It was evident from the extant experimental results that **CM-CN** exhibited exceptional suitability for  $\text{H}_2\text{O}_2$  monitoring in both cellular and zebrafish models. Building upon these findings, we further validated the capacity of **CM-CN** for real-time  $\text{H}_2\text{O}_2$  detection in living mice, particularly focusing on its application in NAFLD models. Given the well-established correlation between elevated  $\text{H}_2\text{O}_2$  levels and hepatic steatosis,<sup>43–46</sup> we established a NAFLD mouse model through high-fat diet (HFD) feeding combined with daily intraperitoneal DXM injections (100 mg  $\text{kg}^{-1}$ ), while control animals received standard chow and saline injections. Following a 7-day induction period, all animals received intraperitoneal **CM-CN** injections (100 mg  $\text{kg}^{-1}$ ) for *in vivo*  $\text{H}_2\text{O}_2$  monitoring. Fluorescence imaging analysis (Fig. 6) revealed that the fluorescence in the abdomen of NAFLD mice was significantly enhanced compared to the control group, with the strongest signal reaching more than five times that of the control group at the corresponding time point. Furthermore, the signal in the liver region underwent a gradual enhancement over time, with the signal persisting for a duration of 3 h without any discernible dissipation. This observation substantiates the remarkable temporal stability exhibited by **CM-CN**. These findings not only validated the capability of **CM-CN** for real-time  $\text{H}_2\text{O}_2$  monitoring in complex mammalian systems but also established its potential as a diagnostic tool for evaluating therapeutic efficacy in liver-related pathologies, thereby contri-



**Fig. 6** *In vivo* fluorescence images of mice: (A) normal mice and experimental group mice injected intraperitoneally with CM-CN ( $100 \text{ mg kg}^{-1}$ ) at 0, 60, 120 and 180 min ( $\lambda_{\text{ex}} = 460 \text{ nm}$ ,  $\lambda_{\text{em}} = 565 \text{ nm}$ ). (B) The relative fluorescence intensity of the picture from (A). Data are presented as mean SEM (bars) ( $n = 6$ ).

buting to the development of novel diagnostic and therapeutic strategies for oxidative stress-associated diseases.

## 4. Conclusions

In conclusion, a fluorescent probe reactive to  $\text{H}_2\text{O}_2$ , designated CM-CN, was designed and synthesized, which reacts with  $\text{H}_2\text{O}_2$ , subsequently generating fluorescence *in situ* by means of a self-assembled tandem cyclisation reaction, thus effectively reducing interference from the autofluorescence of the probe. The novel molecular structure under consideration has been demonstrated to offer excellent sensitivity, selectivity and anti-interference properties for the detection of  $\text{H}_2\text{O}_2$ . In addition, CM-CN has been observed to exhibit low toxicity and high biocompatibility. Based on these properties, a variety of biological models have been imaged, with the results demonstrating the excellent photostability of the probe and its ability to detect  $\text{H}_2\text{O}_2$  in bioimaging. These combined attributes position CM-CN as a transformative tool for advancing fundamental research in reactive oxygen species biology and clinical translation of redox-targeted therapeutic strategies, particularly in hepatic steatosis and oxidative stress-related disorders.

## Author contributions

Mengzhao Zhang: data curation, formal analysis, software, and writing – original draft. Junlei Hao: formal analysis, methodology, and writing – review & editing. ChengCheng Wu: formal analysis and compound synthesis. Suntao Shi: investigation and project administration. Zhengyu Ma: data curation, formal analysis, compound synthesis. Xiaowen Ren: software, writing-review & editing. Fei Han: compound synthesis, investigation, software. Jiang Wu: investigation, funding acquisition. Haijuan Zhang: software, funding acquisition. Baoxin Zhang: funding acquisition, supervision, and writing – review & editing.

## Conflicts of interest

The authors declare no conflict of interest.

## Data availability

The data supporting this article have been included in the SI. See DOI: <https://doi.org/10.1039/d5ob00406c>.

## Acknowledgements

Financial support from the Natural Science Foundation of Gansu Province (24JRRA384, 25JRRA1125 and 25JRRA667), the National Natural Science Foundation of China (21708017 and 22206067), and the Science and Technology Major Program of Gansu Province of China (22ZD6FA006, 23ZDFA015, and 24ZD13FA017) is acknowledged.

## References

- 1 C. A. Bradley, *Nat. Rev. Gastroenterol. Hepatol.*, 2017, **14**, 139.
- 2 X. Ren, Z. N. Sayed, S. Shi, J. Hao, J. Gao, J. Wu, H. Zhang, Z. Liu and B. Zhang, *Talanta*, 2025, **286**, 127470.
- 3 Y. Hu, H. Li, H. Zhang, X. Chen, J. Chen, Z. Xu, H. You, R. Dong, Y. Peng, J. Li, X. Li, D. Wu, L. Zhang, D. Cao, H. Jin, D. Qiu, A. Yang, J. Lou, X. Zhu, J. Niu and Y. Ding, *Nat. Commun.*, 2023, **14**, 6409.
- 4 N. R. Powell, T. Liang, J. Ipe, S. Cao, T. C. Skaar, Z. Desta, H.-R. Qian, P. J. Ebert, Y. Chen, M. K. Thomas and N. Chalasani, *Nat. Commun.*, 2023, **14**, 1474.
- 5 S. Han, Y. Zeng, Y. Li, H. Li, L. Yang, X. Ren, M. Lan, B. Wang and X. Song, *Anal. Chem.*, 2023, **95**, 18619–18628.
- 6 J. Hao, X. Li, S. Shi, H. Zhang, H. Zhu, J. Wu, M. Gao and B. Zhang, *Bioorg. Chem.*, 2025, **155**, 108162.
- 7 K. Ray, *Nat. Rev. Gastroenterol. Hepatol.*, 2018, **15**, 130–131.
- 8 B. Hu, Q. Liu, Y. Jiang, Y. Huang, H. Ji, J. Zhang, X. Wang, X.-C. Shen and H. Chen, *Angew. Chem., Int. Ed.*, 2025, **64**, e202418378.
- 9 M. Abo, Y. Urano, K. Hanaoka, T. Terai, T. Komatsu and T. Nagano, *J. Am. Chem. Soc.*, 2011, **133**, 10629–10637.
- 10 C. C. Winterbourn, *Nat. Chem. Biol.*, 2008, **4**, 278–286.
- 11 S. Ye, J. J. Hu and D. Yang, *Angew. Chem., Int. Ed.*, 2018, **57**, 10173–10177.
- 12 W. Zhang, T. Liu, F. Huo, P. Ning, X. Meng and C. Yin, *Anal. Chem.*, 2017, **89**, 8079–8083.
- 13 T. Akaike, T. Ida, F. Y. Wei, M. Nishida, Y. Kumagai, M. M. Alam, H. Ihara, T. Sawa, T. Matsunaga, S. Kasamatsu, A. Nishimura, M. Morita, K. Tomizawa, A. Nishimura, S. Watanabe, K. Inaba, H. Shima, N. Tanuma, M. Jung, S. Fujii, Y. Watanabe, M. Ohmuraya, P. Nagy, M. Feelisch, J. M. Fukuto and H. Motohashi, *Nat. Commun.*, 2017, **8**, 1177.
- 14 I. Leong, *Nat. Rev. Endocrinol.*, 2018, **14**, 190.
- 15 Q. Zan, K. Zhao, R. Li, Y. Yang, X. Yang, W. Li, G. Zhang, C. Dong, S. Shuang and L. Fan, *Anal. Chem.*, 2024, **96**, 10488–10495.
- 16 N. Wang, X. Lu, J. Wang, H. Wang, B. Zhang, W. Zhao and J. Zhang, *Anal. Chem.*, 2023, **95**, 5967–5975.

- 17 S. Peng, B. Zhang, X. Meng, J. Yao and J. Fang, *J. Med. Chem.*, 2015, **58**, 5242–5255.
- 18 X. Liu, Z. Liu, Y. Li, Y. Wang and W. Zhang, *Org. Biomol. Chem.*, 2025, **23**, 1708–1713.
- 19 D. Zhu, A. Ren and L. Xue, *Org. Biomol. Chem.*, 2024, **22**, 9113–9120.
- 20 Z. Yang, Z. Wang, Y. Peng, H. Yang, Q. Wang, X. Jia and X. Liu, *Org. Biomol. Chem.*, 2024, **22**, 8024–8031.
- 21 S. Das, A. Chaudhuri, H. K. Indurthi, A. K. Agrawal and D. K. Sharma, *Org. Biomol. Chem.*, 2024, **22**, 7332–7336.
- 22 L. Wang, Y. Huang, J. Wang, Y. Jiang, B.-P. Jiang, H. Chen, H. Liang and X.-C. Shen, *J. Am. Chem. Soc.*, 2025, **147**, 6707–6716.
- 23 D. Pham, U. Basu, I. Pohorilets, C. M. S. Croix, S. C. Watkins and K. Koide, *Angew. Chem., Int. Ed.*, 2020, **59**, 17435–17441.
- 24 Q. Zan, K. Zhao, R. Li, Y. Yang, X. Yang, W. Li, G. Zhang, C. Dong, S. Shuang and L. Fan, *Anal. Chem.*, 2024, **96**, 10488–10495.
- 25 W.-X. Wang, W.-L. Jiang, G.-J. Mao, M. Tan, J. Fei, Y. Li and C.-Y. Li, *Anal. Chem.*, 2021, **93**, 3301–3307.
- 26 N. Decha, J. Thonglam, J. Meesane, S. Pornsuwan and C. Tansakul, *Org. Biomol. Chem.*, 2024, **22**, 1254–1268.
- 27 E. W. Miller, A. E. Albers, A. Pralle, E. Y. Isacoff and C. J. Chang, *J. Am. Chem. Soc.*, 2005, **127**, 16652–16659.
- 28 J. Shin, P. Verwilst, H. Choi, S. Kang, J. Han, N. H. Kim, J. G. Choi, M. S. Oh, J. S. Hwang, D. Kim, I. Mook-Jung and J. S. Kim, *Angew. Chem., Int. Ed.*, 2019, **58**, 5648–5652.
- 29 D. Kim, S. Singha, T. Wang, E. Seo, J. H. Lee, S.-J. Lee, K. H. Kim and K. H. Ahn, *Chem. Commun.*, 2012, **48**, 10243–10245.
- 30 J. J. O'Sullivan and M. C. Heffern, *Org. Biomol. Chem.*, 2022, **20**, 6231–6238.
- 31 L. Meng, Z. Xu, J. Chen, H. Luo and N. Li, *Anal. Chim. Acta*, 2024, **1308**, 342660.
- 32 C. Luo, Y. Chen, J. Gu, H. Cai, H. Lin, Z. Jin and C. Huang, *Anal. Chem.*, 2024, **96**, 9969–9974.
- 33 P. Wang, L. Yu, J. Gong, J. Xiong, S. Zi, H. Xie, F. Zhang, Z. Mao, Z. Liu and J. S. Kim, *Angew. Chem., Int. Ed.*, 2022, **61**, e202206894.
- 34 C. Wu, H. Wei, S. Shi, Z. Wang, Z. Zhang, A. Osama, J. Wu, H. Zhang and B. Zhang, *J. Mater. Chem. B*, 2025, **13**, 2067–2073.
- 35 K. Ma, L. Zhao, Y. Yue, F. Huo, J. Chao and C. Yin, *Anal. Chem.*, 2020, **92**, 15936–15942.
- 36 W. Zhang, Q. Jia, Y. Meng, S. Chen, Y. Zhang, K.-P. Wang, L.-H. Gan and Z.-Q. Hu, *Spectrochim. Acta, Part A*, 2020, **228**, 117835.
- 37 A. Declémy, C. Rulliere and P. Kottis, *Chem. Phys. Lett.*, 1983, **101**, 401–406.
- 38 H. Wang, J. Guo, T. Xiu, Y. Tan, P. Li, W. Zhang, W. Zhang and B. Tang, *Chem. Sci.*, 2025, **16**, 345–353.
- 39 D. Maity, A. Raj, P. K. Samanta, D. Karthigeyan, T. K. Kundu, S. K. Pati and T. Govindaraju, *RSC Adv.*, 2014, **4**, 11147–11151.
- 40 L. Fan, Q. Zan, X. Wang, X. Yu, S. Wang, Y. Zhang, Q. Yang, W. Lu, S. Shuang and C. Dong, *Chem. Eng. J.*, 2022, **449**, 137762.
- 41 B. C. Dickinson, C. Huynh and C. J. Chang, *J. Am. Chem. Soc.*, 2010, **132**, 5906–5915.
- 42 X. Bai, Y. Huang, M. Lu and D. Yang, *Angew. Chem., Int. Ed.*, 2017, **56**, 12873–12877.
- 43 N. Wang, X. Lu, J. Wang, H. Wang, B. Zhang, W. Zhao and J. Zhang, *Anal. Chem.*, 2023, **95**, 5967–5975.
- 44 B. Zhang, S. Qin, N. Wang, X. Lu, J. Jiao, J. Zhang and W. Zhao, *Talanta*, 2024, **266**, 124971.
- 45 G. Fan, B. Zhang, J. Wang, N. Wang, S. Qin, W. Zhao and J. Zhang, *Talanta*, 2024, **268**, 125298.
- 46 J. Liu, X. Liu, Y. Shan, H. Ting, X. Yu, J.-W. Wang and B. Liu, *Biomaterials*, 2024, **306**, 122506.